Yuhan (XKRX:000100) ROCE % : 3.17% (As of Mar. 2024)

View and export this data going back to 1962. Start your Free Trial

What is Yuhan ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Yuhan's annualized ROCE % for the quarter that ended in Mar. 2024 was 3.17%.

Yuhan ROCE % Historical Data

The historical data trend for Yuhan's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yuhan ROCE % Chart

Yuhan Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

3.23

12.85

6.38

4.83

6.60

Yuhan Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															7.22	2.90	4.09	12.36	3.17

Yuhan ROCE % Calculation

Yuhan's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	140839.609	/	( ( (2472728.072 - 434154.259)	+	(2814070.522 - 583192.369) )	/ 2 )
	=	140839.609	/	( (2038573.813	+	2230878.153)	/ 2 )
	=	140839.609	/	2134725.983
	=	6.60 %

Yuhan's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	70757.056	/	( ( (2814070.522 - 583192.369)	+	(2801252.649 - 562112.382) )	/ 2 )
	=	70757.056	/	( ( 2230878.153	+	2239140.267 )	/ 2 )
	=	70757.056	/	2235009.21
	=	3.17 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Yuhan (XKRX:000100) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Yuhan ROCE % Related Terms

Thank you for viewing the detailed overview of Yuhan's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Yuhan (XKRX:000100) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Yuhan Corp (XKRX:000100) » Definitions » ROCE %

Traded in Other Exchanges

000105:Korea

Address

74, Noryangjin-ro, Dongjak-gu, Seoul, KOR

Website

http://www.yuhan.co.kr

Yuhan Corp is a pharmaceutical company. The core business of the company is classified as primary and specialty care, dietary supplement, household and animal care, and contract manufacturing of active pharmaceutical ingredients. Yuhan offers one-stop custom synthesis services from research and development to commercial production of active pharmaceutical products (APIs) and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets.

Yuhan (XKRX:000100) Headlines

No Headlines